# A Patent on Your Improvement Does Not Necessarily Give You the Right to Sell It By Charles Gideon Korrell (@charlesgideonkorrell) ยท Published 2026-09-05 Canonical: https://voce.com/@charlesgideonkorrell/patent-improvement-freedom-to-operate-uva811 --- Obtaining a patent can feel like receiving government approval to commercialize an invention. It is not. A patent generally gives its owner the right to prevent others from practicing the claimed invention. It does not automatically give the owner permission to make or sell the invention itself. An earlier, broader patent may still cover the product, even when the later inventor has obtained a patent on a genuine improvement. A recent Federal Circuit decision involving the cancer drug Cabometyx illustrates the distinction and why businesses developing improved versions of existing technology need to consider patentability and freedom to operate separately. ## A New Form Can Still Fall Within an Older Patent Exelixis developed cabozantinib (L)-malate, the active ingredient in Cabometyx. The compound can exist in different crystalline arrangements, known as polymorphs. Different polymorphs of the same compound may have different properties, such as stability, solubility, or melting point. Exelixis had patents broadly covering crystalline cabozantinib (L)-malate. MSN Laboratories later developed a different crystalline form, called Form S, and obtained its own patent on that form. But MSN's patent did not place Form S outside the scope of Exelixis's earlier patents. In litigation over MSN's proposed generic product, MSN conceded that its product infringed Exelixis's broader claims and instead argued that those claims were invalid. That distinction is commercially important. An improvement can be sufficiently new and inventive to deserve its own patent while simultaneously falling within an earlier patent owned by someone else. ## Why the Earlier Patent Survived MSN argued that Exelixis's patents were too broad because the patent documents expressly characterized only two crystalline forms, while the claims covered crystalline cabozantinib (L)-malate more generally. Patent law requires the original patent disclosure to show that the inventor actually possessed what was later claimed. For a claim covering a group of related things, this can sometimes be demonstrated by describing representative examples. But there is another route: the patent can identify structural characteristics that allow knowledgeable people in the field to recognize what belongs within the claimed group. The Federal Circuit concluded that the trial court could reasonably find that Exelixis had done that. The patents identified the specific chemical compound by name and formula and required it to be crystalline rather than amorphous. The possible group of crystalline forms was also comparatively limited, and the claims did not require every form to have the same performance characteristics. The court therefore affirmed the finding that the broader claims were adequately described. The decision does not mean that describing one or two examples will always support a patent claim covering every variation. The court's reasoning depended on the particular disclosure, the structural characteristics used to define the group, and the relatively limited range of possible forms. ## Patentability and Freedom to Operate Are Different Questions For businesses developing improved technology, the larger lesson is that two patent questions should not be confused. The first is whether an improvement is patentable. The second is whether the business has freedom to operate, meaning whether making or selling the improved product would infringe someone else's existing patent rights. The answers can be "yes" to the first and "no" to the second. That situation is common enough to affect product development, licensing, investment, and acquisition strategy. A company may own valuable intellectual property covering an improvement but still need a license from the owner of an earlier foundational patent before commercializing it. Conversely, the owner of the earlier patent may want access to the later improvement, creating opportunities for licensing or cross-licensing. ## Check the Patent Landscape Before Commercialization The practical point is not to treat issuance of a patent as a freedom-to-operate clearance. When a product builds on an existing technology, particularly one in a patent-intensive field, the relevant analysis should include earlier patents whose claims may be broader than the new improvement. That review can affect decisions about product design, licensing, launch timing, investment, and negotiations with other patent owners. It is often far less expensive to identify blocking rights before commercialization than after substantial development or a product launch. For readers interested in the Federal Circuit's written-description analysis and the other issues addressed in the decision, a more detailed discussion is available in the [Technology & Information Law Blog article on Exelixis v. MSN Laboratories](https://techinfolaw.com/exelixis-v-msn-labs/?utm_source=chatgpt.com). **About the Author:** Charles Gideon Korrell is a technology-transactions attorney and strategic advisor whose practice focuses on technology licensing, commercial transactions, intellectual property strategy, and related matters. More information about his practice is available at [GideonKorrell.com](http://GideonKorrell.com). He publishes the Technology & Information Law Blog at [TechInfoLaw.com](http://TechInfoLaw.com), where he provides more detailed analysis of judicial decisions and legal developments affecting technology and intellectual property.